Bajaj HealthCare
472.30
-22.30(-4.51%)
Market Cap₹1,491.70 Cr
PE Ratio31.68
IndustryHealthcare
Company Performance:
1D-4.51%
1M+8.67%
6M-32.83%
1Y+22.47%
5Y+30.13%
View Company Insightsright
Latest news about Bajaj HealthCare
More news about Bajaj HealthCare
26May 25
Bajaj Healthcare Reports Q4 Profit Turnaround and Announces Dividend
Bajaj Healthcare Limited's Q4 results show a significant improvement, with revenue increasing by 14.93% to ₹154.00 crore. The company returned to profitability with a net profit of ₹11.18 crore, compared to a loss of ₹29.92 crore in the same quarter last year. Despite EBITDA declining to ₹11.76 crore and margins contracting to 7.61%, the board recommended a final dividend of ₹1.00 per equity share.
10Apr 25
Bajaj Healthcare Strengthens Financial Leadership with Appointment of Rohan Parekh as CFO
Bajaj Healthcare Limited has appointed Mr. Rohan Parekh as the new Chief Financial Officer (CFO) and Key Managerial Personnel, effective April 16, 2025. Mr. Parekh, a qualified chartered accountant with over 13 years of experience, brings expertise in corporate strategy, financial planning, and treasury management. Additionally, the company has granted 2,500 stock options to employees under its 2024 ESOP plan, with an exercise price of Rs. 5.00 per option.
08Apr 25
Bajaj Healthcare Expands with Genrx Pharmaceuticals Acquisition, Considers Bonus Shares
Bajaj Healthcare Limited has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in an all-cash deal, gaining 100% control. The acquisition, completed on April 4, 2025, aims to expand Bajaj Healthcare's manufacturing capabilities. Genrx Pharmaceuticals is a WHO-GMP certified manufacturer specializing in allopathic formulations, nutraceuticals, and natural products. The integration is expected to take 3-6 months, pending regulatory approvals. Additionally, Bajaj Healthcare's board will meet on April 16 to consider issuing bonus shares.
07Apr 25
Bajaj Healthcare Expands Manufacturing Capabilities with ₹10.85 Crore Acquisition of Genrx Pharmaceuticals
Bajaj Healthcare Limited (BHL) has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in cash, gaining 100% control. Genrx, a WHO-GMP certified manufacturer, specializes in allopathic formulations, nutraceuticals, and natural products. The acquisition expands BHL's manufacturing portfolio, strengthening its position in the pharmaceutical sector. The deal is expected to close in 3-6 months, pending regulatory approvals.
03Apr 25
Bajaj Healthcare CFO Dayashankar Patel Resigns, Effective April 15
Bajaj Healthcare Limited (BHL) announced the resignation of CFO Dayashankar Patel, effective April 15, 2025, citing personal reasons. The company appreciated his services and confirmed no material reasons for the resignation beyond those stated. The announcement complies with SEBI regulations, and BHL is expected to manage the transition in financial leadership.
02Apr 25
Bajaj Healthcare CFO Dayashankar Patel Steps Down, Citing Personal Reasons
Bajaj Healthcare Limited announced that its Chief Financial Officer (CFO), Dayashankar Patel, has resigned due to personal reasons. Patel will be relieved from his duties as CFO and Key Managerial Personnel after April 15, 2025. The company expressed appreciation for Patel's services and confirmed no material reasons for the resignation beyond those stated. The announcement was made on April 2, 2025, allowing for a brief transition period. Bajaj Healthcare has complied with SEBI regulations by disclosing the change to relevant stock exchanges. No successor has been announced yet.
Bajaj HealthCare
472.30
-22.30
(-4.51%)
1 Year Returns:+22.47%
Industry Peers
Sun Pharmaceutical
1,586.70
(-2.50%)
Divis Laboratories
5,689.50
(-3.52%)
Cipla
1,499.40
(-0.68%)
Torrent Pharmaceuticals
3,561.00
(+0.83%)
Dr Reddys Laboratories
1,253.10
(-1.73%)
Mankind Pharma
2,482.90
(-1.71%)
Zydus Life Science
975.00
(-4.34%)
Lupin
1,919.80
(-2.23%)
Alkem Laboratories
5,433.00
(-1.36%)
Aurobindo Pharma
1,090.00
(-0.64%)